tbuckley/cabot-search huggingface dataset:
Cancer statistics, 2018
Authors: Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal
Journal: CA A Cancer Journal for Clinicians (2018)

Abstract Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States and compiles the most recent data on cancer incidence, mortality, and survival. Incidence data, available through 2014, were collected by the Surveillance, Epidemiology, and End Results Program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries. Mortality data, available through 2015, were collected by the National Center for Health Statistics. In 2018, 1,735,350 new cancer cases and 609,640 cancer deaths are projected to occur in the United States. Over the past decade of data, the cancer incidence rate (2005‐2014) was stable in women and declined by approximately 2% annually in men, while the cancer death rate (2006‐2015) declined by about 1.5% annually in both men and women. The combined cancer death rate dropped continuously from 1991 to 2015 by a total of 26%, translating to approximately 2,378,600 fewer cancer deaths than would have been expected if death rates had remained at their peak. Of the 10 leading causes of death, only cancer declined from 2014 to 2015. In 2015, the cancer death rate was 14% higher in non‐Hispanic blacks (NHBs) than non‐Hispanic whites (NHWs) overall (death rate ratio [DRR], 1.14; 95% confidence interval [95% CI], 1.13‐1.15), but the racial disparity was much larger for individuals aged &lt;65 years (DRR, 1.31; 95% CI, 1.29‐1.32) compared with those aged ≥65 years (DRR, 1.07; 95% CI, 1.06‐1.09) and varied substantially by state. For example, the cancer death rate was lower in NHBs than NHWs in Massachusetts for all ages and in New York for individuals aged ≥65 years, whereas for those aged &lt;65 years, it was 3 times higher in NHBs in the District of Columbia (DRR, 2.89; 95% CI, 2.16‐3.91) and about 50% higher in Wisconsin (DRR, 1.78; 95% CI, 1.56‐2.02), Kansas (DRR, 1.51; 95% CI, 1.25‐1.81), Louisiana (DRR, 1.49; 95% CI, 1.38‐1.60), Illinois (DRR, 1.48; 95% CI, 1.39‐1.57), and California (DRR, 1.45; 95% CI, 1.38‐1.54). Larger racial inequalities in young and middle‐aged adults probably partly reflect less access to high‐quality health care. CA Cancer J Clin 2018;68:7‐30 . © 2018 American Cancer Society .
<i>JAMA Pediatrics</i> 2018 and Beyond
Authors: Dimitri A. Christakis
Journal: JAMA Pediatrics (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Development of Adherence Questionnaire for Children and Adolescents with Asthma
Authors: Takao Fujisawa, Mizuho Nagao, Yumi Mizuno, Naoki Shimojo, Natoka Itoh-Nagato, Yukihiro Ohya, Takanori Imai, Motohiro Ebisawa, Chizu Habukawa, Hiroshi Odajima, Yasunori Sato
Journal: Journal of Allergy and Clinical Immunology (2018)
Mechanosensing and fibrosis
Authors: Daniel J. Tschumperlin, Giovanni Ligresti, Moira B. Hilscher, Vijay H. Shah
Journal: Journal of Clinical Investigation (2018)

Tissue injury disrupts the mechanical homeostasis that underlies normal tissue architecture and function. The failure to resolve injury and restore homeostasis gives rise to progressive fibrosis that is accompanied by persistent alterations in the mechanical environment as a consequence of pathological matrix deposition and stiffening. This Review focuses on our rapidly growing understanding of the molecular mechanisms linking the altered mechanical environment in injury, repair, and fibrosis to cellular activation. In particular, our focus is on the mechanisms by which cells transduce mechanical signals, leading to transcriptional and epigenetic responses that underlie both transient and persistent alterations in cell state that contribute to fibrosis. Translation of these mechanobiological insights may enable new approaches to promote tissue repair and arrest or reverse fibrotic tissue remodeling.
A Comparison of One Year Outcomes in ZUMA-1 (axicabtagene ciloleucel) and SCHOLAR-1 in Patients with Refractory, Aggressive Non-Hodgkinlymphoma (NHL)
Authors: Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett, Lazaros J. Lekakis, Patrick M. Reagan, David B. Miklos, Caron A. Jacobson, Ira Braunschweig, Olalekan O. Oluwole, Tanya Siddiqi, Yi Lin, Michael Crump, John Kuruvilla, Eric W. Van Den Neste, Umar Farooq, Lynn Navale, William Y. Go, Jeffrey S. Wiezorek, Christian Gisselbrecht
Journal: Blood (2017)
The Bronchiectasis Severity Index and FACED score for assessment of the severity of bronchiectasis
Authors: J.C. Costa, J.N. Machado, C. Ferreira, J. Gama, C. Rodrigues
Journal: Pulmonology (2018)

Bronchiectasis (BC) is a multidimensional and etiologically diverse disease and, therefore, no single parameter can be used to determine its overall severity and prognosis. In this regard, two different validated scores are currently used to assess the severity of non-cystic fibrosis bronchiectasis (NCFB): the FACED score and the Bronchiectasis Severity Index (BSI).
Risk factors and comorbidities of allergic rhinitis phenotype in children according to ARIA classification
Authors: Sungsu Jung, Jisun Yoon, Hyun-ju Cho, Young-Ho Kim, Dong In Suh, Song-I. Yang, Ji-Won Kwon, Gwang-Cheon Jang, Yong Han Sun, Sung Il Woo, You Sook Youn, Kang Seo Park, Hwa Jin Cho, Myung Hee Kook, Hye Ryoung Yi, Hai Lee Chung, Ja Hyeong Kim, Hyung Young Kim, Jin A. Jung, Hyang Ok Woo
Journal: Journal of Allergy and Clinical Immunology (2018)
Clinical and Serological Characteristics of Cold Autoimmune Hemolytic Anemia with Concomitant Cold Agglutinin and Donath-Landsteiner Antibodies
Authors: Aishwarya Ravindran, Eapen K. Jacob, Justin D. Kreuter, Sheila K. Moldenhauer, Rajiv K. Pruthi, C. Christopher Hook, Timothy G. Call, Alexandra P. Wolanskyj-Spinner, Ariela L. Marshall, Aneel A. Ashrani, Kebede H. Begna, Neil E. Kay, Jeffrey L. Winters, Ronald S. Go
Journal: Blood (2017)
<i>TP53</i> Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children
Authors: Maoxiang Qian, Xueyuan Cao, Meenakshi Devidas, Wenjian Yang, Cheng Cheng, Yunfeng Dai, Andrew Carroll, Nyla A. Heerema, Hui Zhang, Takaya Moriyama, Julie M. Gastier-Foster, Heng Xu, Elizabeth Raetz, Eric Larsen, Naomi Winick, W. Paul Bowman, Paul L. Martin, Elaine R. Mardis, Robert Fulton, Gerard Zambetti, Michael Borowitz, Brent Wood, Kim E. Nichols, William L. Carroll, Ching-Hon Pui, Charles G. Mullighan, William E. Evans, Stephen P. Hunger, Mary V. Relling, Mignon L. Loh, Jun J. Yang
Journal: Journal of Clinical Oncology (2018)

Purpose Germline TP53 variation is the genetic basis of Li-Fraumeni syndrome, a highly penetrant cancer predisposition condition. Recent reports of germline TP53 variants in childhood hypodiploid acute lymphoblastic leukemia (ALL) suggest that this type of leukemia is another manifestation of Li-Fraumeni syndrome; however, the pattern, prevalence, and clinical relevance of TP53 variants in childhood ALL remain unknown. Patients and Methods Targeted sequencing of TP53 coding regions was performed in 3,801 children from the Children's Oncology Group frontline ALL clinical trials, AALL0232 and P9900. TP53 variant pathogenicity was evaluated according to experimentally determined transcriptional activity, in silico prediction of damaging effects, and prevalence in non-ALL control populations. TP53 variants were analyzed for their association with ALL presenting features and treatment outcomes. Results We identified 49 unique nonsilent rare TP53 coding variants in 77 (2.0%) of 3,801 patients sequenced, of which 22 variants were classified as pathogenic. TP53 pathogenic variants were significantly over-represented in ALL compared with non-ALL controls (odds ratio, 5.2; P < .001). Children with TP53 pathogenic variants were significantly older at ALL diagnosis (median age, 15.5 years v 7.3 years; P < .001) and were more likely to have hypodiploid ALL (65.4% v 1.2%; P < .001). Carrying germline TP53 pathogenic variants was associated with inferior event-free survival and overall survival (hazard ratio, 4.2 and 3.9; P < .001 and .001, respectively). In particular, children with TP53 pathogenic variants were at a dramatically higher risk of second cancers than those without pathogenic variants, with 5-year cumulative incidence of 25.1% and 0.7% ( P < .001), respectively. Conclusion Loss-of-function germline TP53 variants predispose children to ALL and to adverse treatment outcomes with ALL therapy, particularly the risk of second malignant neoplasms.
A phase 1, open-label, dose escalation study of enoblituzumab (MGA271) in pediatric patients with B7-H3-expressing relapsed or refractory solid tumors.
Authors: Kenneth Desantes, John M. Maris, Kimberly McDowell, Crystal Mackall, Sadhna Shankar, Jim Vasselli, Francine Chen, Deryk Loo, Paul A. Moore, Jon M. Wigginton, Paul M. Sondel
Journal: Journal of Clinical Oncology (2017)

TPS2596 Background: Enoblituzumab, is an Fc optimized humanized IgG1 monoclonal antibody that binds to B7-H3 (CD276), a member of the B7 family. It is Fc-engineered to enhance effector function including antibody dependent cellular cytotoxicity (ADCC). IHC analyses with the parental anti-B7H3 mAb specificity incorporated in enoblituzmab revealed limited B7-H3 expression in normal tissues but high expression in many cancers (Loo et al., 2012). Among pediatric solid tumors, high expression of B7-H3 has been reported in neuroblastoma, rhabdomyosarcoma, osteosarcoma, Wilms tumor, Ewing’s sarcoma and desmoplastic small round cell tumor. B7-H3 overexpression correlates with poor prognosis in a broad range of cancers in adults suggesting a potential role in enabling tumor immune escape. ADCC and potential modulation of T cell function resulting in enhanced antitumor immune response are presumed mechanisms of action of enoblituzumab. Methods: This is an open-label, dose escalation / cohort expansion phase 1 study (NCT02982941) designed to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of enoblituzumab in children and young adults with B7-H3-expressing relapsed or refractory malignant solid tumors. A 3+3 design is used in escalating dose cohorts of weekly intravenous (IV) enoblituzumab starting at 10 mg/kg. Response is first determined at 8 weeks. irRECIST is used for response assessment for patient management. Enoblituzumab may continue up to 2 years based on response. Cohort expansion phase, to further define the safety and initial antitumor activity of enoblituzumab, will start after maximum tolerated dose is determined. The patients are assigned to 1 of 5 cohorts based on disease type as follows: 1) neuroblastoma - measurable disease, 2) neuroblastoma - non-measurable disease, 3) rhabdomyosarcoma, 4) osteosarcoma, and 5) Ewing’s sarcoma, Wilms’ tumor and desmoplastic small round cell tumors. Enrollment is ongoing. Ref : Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity. Loo D, Alderson RF, Chen FZ, Huang L et al. Clin Cancer Res. 2012; 18:3834-45. Clinical trial information: NCT02982941.
Abstract 19673: The Association Between Peripheral Blood Levels of B Regulatory Lymphocytes and Clinically Unstable Coronary Artery Disease
Authors: Igor Volodarsky, Dan Haberman, Sara Shimoni, Yaakov Fabrikant, Adi Zalik, Jacob George
Journal: Circulation (2016)

Background: Inflammatory processes within the atherosclerotic plaque are related to plaque instability with consequent acute coronary syndromes (ACS). The levels and the activity of several anti-in...
A Phenotypically Distinct Subset of Eosinophils is Recovered with Intestinal Intraepithelial Leukocytes
Authors: Yanjun Huang, Dilanjan T. Anketell, Jason J. Xenakis, Kalmia Smith, Courtney L. Olbrich, Evangeline W. Cornwell, Emily D. Ericson, Lisa A. Spencer
Journal: Journal of Allergy and Clinical Immunology (2018)
A minimental status examination
Journal: BMJ (1997)

بررسی نمره mini mental status examination در جمعیت بالای ۵۵ ساله شهر بوشهر , بررسی نمره mini mental status examination در جمعیت بالای ۵۵ ساله شهر بوشهر , کتابخانه دانشگاه علوم پزشکی و خدمات درمانی بوشهر
Chemoradiotherapy Versus Chemotherapy Alone for Unresected Nonmetastatic Gallbladder Cancer: National Practice Patterns and Outcomes
Authors: Vivek Verma, Swati M. Surkar, Eric D. Brooks, Charles B. Simone, Chi Lin
Journal: Journal of the National Comprehensive Cancer Network (2018)

Purpose: Current guidelines recommend chemotherapy (CT) with or without radiotherapy for unresected nonmetastatic gallbladder cancer (GC), with little consensus. However, several small-volume, single-institution studies have documented the efficacy of local therapy for this population. This is the largest study to date evaluating outcomes of chemoradiotherapy (CRT) versus CT alone in unresected nonmetastatic GC. Methods: The National Cancer Database was queried for primary GC cases (2004-2013) receiving CT alone or CRT. Patients receiving resection or lack of CT were excluded, as were those with metastatic disease or unknown M classification. Logistic regression analysis ascertained factors associated with CRT delivery. Kaplan-Meier analysis evaluated overall survival (OS) between both cohorts. Cox proportional hazards modeling determined variables associated with OS. Results: In total, 1,199 patients were analyzed (CRT: n=327, 27%; CT: n=872, 73%). Groups were evenly balanced, with no factor on multivariate logistic regression analysis statistically predicting for receipt of a particular paradigm. Median OS in the CRT and CT groups was 12.9 versus 7.8 months, respectively (P=.001). On multivariate analysis, OS was associated with age and years of treatment (P=.001 each). Notably, receipt of CRT independently predicted for improved OS (P=.001). Conclusions: CRT, compared with CT alone, was independently associated with improved survival in unresected nonmetastatic GC. Although causation is not implied, these results support the necessity for prospective CRT evaluation.
Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia
Authors: Karen L. Bride, Tiffaney L. Vincent, Soo-Yeon Im, Richard Aplenc, David M. Barrett, William L. Carroll, Robin Carson, Yunfeng Dai, Meenakshi Devidas, Kimberly P. Dunsmore, Tori Fuller, Tina Glisovic-Aplenc, Terzah M. Horton, Stephen P. Hunger, Mignon L. Loh, Shannon L. Maude, Elizabeth A. Raetz, Stuart S. Winter, Stephan A. Grupp, Michelle L. Hermiston, Brent L. Wood, David T. Teachey
Journal: Blood (2018)
Patient With Ulcerative Colitis and Abdominal Pain
Authors: Anthony A. Castelli, Joaquin J. Estrada, Jan P. Kaminski
Journal: JAMA Surgery (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Enhanced Abdominal Inflammation In Acute Respiratory Failure - Is The Culprit Ventilator Associated Abdominal Edema Or Inadequate Perfusion? : A Magnetic Resonance Imaging Pilot Study
Authors: Silvia Marchesi, Anders Larsson, Kerstin M. Ahlgren, M. Lattuada, Francisco Ortiz-Nieto, Göran Hedenstierna
Journal: American Journal of Respiratory and Critical Care Medicine (2015)

Enhanced Abdominal Inflammation In Acute Respiratory Failure - Is The Culprit Ventilator Associated Abdominal Edema Or Inadequate Perfusion? : A Magnetic Resonance Imaging Pilot Study
Identification of a 14-gene signature that predicts survival in colorectal cancer with liver metastasis.
Authors: Jo L Chung, Jonathan Pollack, Mei-Sze Chua, Sam So, Chii-Dean Lin, Albert Y. Lin
Journal: Journal of Clinical Oncology (2012)

e14037 Background: Colorectal cancer (CRC) is the third leading cause of cancer death in men and women combined in the USA. Colorectal liver metastasis (CLM), the most common metastasis of CRC, accounts for at least two thirds of CRC deaths. The purpose of this study is to identify a gene signature that predicts patient survival in patients with CLM. Methods: We analyzed the gene expression profiles of specimens from 24 CLM patients (M:F = 14:10) who underwent metastatic liver resection and unmatched primary CRC specimens from an independent cohort of 30 patients (M:F = 14:16). The association between gene expression levels and survival outcome was evaluated using Cox proportional hazards regression. Random Forests and risk scores were used to construct a gene expression-based survival classifier. Results: Based on survival classifier of CLM patients, a 14-gene signature was developed. According to leave-one-out cross validation, all 24 CLM patients (median follow-up time of 25 months) were correctly assigned into high-risk or low-risk groups (p=0.001). This 14-gene signature was then validated in an independent cohort of 30 primary CRC patients (median follow-up time of 42.2 months; p= 0.03) and a subset of 11 patients who were diagnosed at presentation or follow-up with liver metastasis (M:F = 5:6; median follow-up time of 27.6 months; p=0.04). Conclusions: We have identified a 14-gene signature that predicts the survival of CLM patients after liver resection, with validation in an independent cohort. Although sample size is small, the significance level achieved with our survival analysis warrants further investigation of this 14-gene signature in a larger sample size.
Simple integration of fast excitation and offset, delayed inhibition computes directional selectivity in Drosophila
Authors: Eyal Gruntman, Sandro Romani, Michael B. Reiser
Journal: Nature Neuroscience (2018)

A neuron that extracts directionally selective motion information from upstream signals lacking this selectivity must compare visual responses from spatially offset inputs. Distinguishing among prevailing algorithmic models for this computation requires measuring fast neuronal activity and inhibition. In the Drosophila melanogaster visual system, a fourth-order neuron-T4-is the first cell type in the ON pathway to exhibit directionally selective signals. Here we use in vivo whole-cell recordings of T4 to show that directional selectivity originates from simple integration of spatially offset fast excitatory and slow inhibitory inputs, resulting in a suppression of responses to the nonpreferred motion direction. We constructed a passive, conductance-based model of a T4 cell that accurately predicts the neuron's response to moving stimuli. These results connect the known circuit anatomy of the motion pathway to the algorithmic mechanism by which the direction of motion is computed.
Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy
Authors: Steven Coutre, Michael Choi, Richard R. Furman, Herbert Eradat, Leonard Heffner, Jeffrey A. Jones, Brenda Chyla, Lang Zhou, Suresh Agarwal, Tina Waskiewicz, Maria Verdugo, Rod A. Humerickhouse, Jalaja Potluri, William G. Wierda, Matthew S. Davids
Journal: Blood (2018)
German doctors’ leader condemns support for refugee age tests
Authors: Ned Stafford
Journal: BMJ (2018)

The president of the German Medical Association has spoken out against growing political support for mandatory medical tests on refugees who do not possess identification documents but say they are under 18 years of age.

Frank Ulrich Montgomery’s comments came after several politicians endorsed mandatory age tests following the death from stabbing of a 15 year old German girl by a male refugee at the end of December. The male, now in police custody and said to be the victim’s former boyfriend, claims to be 15 years old. However, the father of the victim told the Bild newspaper: “No …
Choice of Hospital as a Source of Racial/Ethnic Disparities in Neonatal Mortality and Morbidity Rates
Authors: Ciaran S. Phibbs, Scott A. Lorch
Journal: JAMA Pediatrics (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Post-Transplant Maintenance Therapy with Azacitidine and Gemtuzumab Ozogamicin for High-Risk Hematologic Malignancies
Authors: Satoshi Kaito, Yuho Najima, Yuya Kishida, Akihito Nagata, Tatsuya Konishi, Yuta Yamada, Shuhei Kurosawa, Kota Yoshifuji, Naoki Matsuyama, Shuichi Shirane, Kyoko Inamoto, Tomoyuki Uchida, Takashi Toya, Aiko Igarashi, Hideharu Muto, Noriko Doki, Takeshi Kobayashi, Kazuhiko Kakihana, Hisashi Sakamaki, Kazuteru Ohashi
Journal: Blood (2017)